Denver, Colorado, United States
Growth Driving Executive and Board member driving revenue and P&L growth through transformational leadership, dynamic commercialization strategies, collaboration, and disciplined operational management. Deep clinical understanding of robotic and minimally invasive surgery with 25+ years of experience enhancing the way surgery is performed for cancer, GI disease, and metabolic health. AREAS OF EXPERTISE: ~Revenue growth and margin improvement ~Commercial strategy and product launches ~Fundraising and investor management ~Clinical trials and FDA clearance ~Innovation and new product development ~Building global KOL networks ~Market modeling and pricing strategy ~Global sales leadership and channel strategies CAREER HIGHLIGHTS: ^ Grew J&J Biosurgery internal startup from $68M to $190M over five years (23% CAGR). ^ Raised $53M for Dextera Surgical leveraging minimally invasive surgery expertise. ^ Accelerated double-digit revenue growth for Conmed with AirSeal Robotic Solution – fastest new product in company history to achieve $10M revenue with 60K procedures (11 months). ^ Reduced cash burn 30% and cost-of-goods 35% for pre-commercial biosurgery company. ^ Cultivated global network of 150+ leading KOL’s in minimally invasive and robotic surgery. ^ Increased Gallup engagement score from 29th to 74th percentile for diverse Conmed commercial team. ^ CEO/Founder of trusted consultancy sought out by medtech investment community throughout career. ^ Co-founded World Congress on Diabetes Surgery expanding CMS reimbursement of bariatric surgery.
Leading corporate strategy, fundraising, product development, clinical evidence generation, and commercialization. Driving development of the first and only real-time, data-driven standardized leak-detection test - digitizing a critical step in surgery that has remained analog for more than 100 years. Built on a disruptive smart constant-flow insufflation platform, Qaelon generates real-time intraoperative data to support AI-driven decision-making across robotic, laparoscopic, and endoluminal surgery. ^ Pivoted Qaelon’s strategy to a dual-capability platform combining digital leak detection with smart constant-flow insufflation, expanding total addressable market from $225M to ~$3B. ^ Accelerated product development and improved clinical workflow efficiency, reducing automated leak-detection testing time from ~2 minutes to <30 seconds while maintaining 100% system accuracy. ^ Created the first open-architecture GI surgical data ecosystem integrating pre, intra, and post-operative technologies through strategic partnerships sharing multimodal surgical data to enable AI-driven surgical intelligence and predictive analytics. ^ Recruited a world-class Scientific Advisory Board and established the first Data Advisory Board in GI surgery, uniting global surgeon innovators, endoscopists, AI experts, and data scientists to guide clinical and data strategy. ^ Led development of the first technology enabling objective confirmation of full-thickness closure integrity in organ-sparing endoluminal surgery.
As an Expert Advisor at AlphaSights, I play a pivotal role in providing strategic insights into minimally invasive surgery, focusing on laparoscopic, robotic, and endoscopy procedures and device companies. By analyzing major industry trends and conducting competitive assessments, I help clients unlock a knowledge advantage in the field to develop innovative strategies and understand drivers of corporate value for investors and strategics.
Trusted executive consultant providing outsourced senior leadership for early-stage medical device startups, product development, and product launches. Clients include Ethicon, KCI, J&J Dermatology, Novartis Diabetes, Modular Medical, Dextera, Z-Medica, Omni-stat Medical, and Cornell University. Select engagements include: ~GENERAL MANAGER, MyAir, Inc. (2021 – 2022). Developed comprehensive US business strategy for hospital grade respiratory monitoring device and consumer wearable platform in treatment of COPD and CHF. ^ Developed strategies for commercialization, fundraising, reimbursement, and regulatory approval. ^ Led business development, strategic partnership implementation, and investor deck development. ^ Authored FDA regulatory submission and Emergency Use Authorization for patients with COVID. ~CHIEF COMMERCIAL OFFICER (Acting) and Board Member, Modular Medical, Inc. (2019 – 2020). Provided commercial leadership and executive coaching to CEO of next generation disposable insulin pump. ^ Developed commercialization strategy, market model, branding, packaging, and pricing. ^ Drove product refinement and feature prioritization aligning marketing strategy, competitive market analysis, and user-based primary market research. ~CHIEF EXECUTIVE OFFICER/CHIEF COMMERCIAL OFFICER, Endo-TAGGS, Inc. (2018 – 2019). CEO/CCO of pre-commercial first and only gastric access trocar for endoscopic treatment of GERD, Obesity, and GI cancer. ^ Created business plan, investor presentation, commercialization strategy, and market model. ^ Reduced COGS by 70% through product design refinements. ^ Expanded IP with two new products increasing total available market (TAM) from $71M to $230M. ^ Developed clinical strategy and pre-clinical labs resulting in two Harvard Medical School publications. ^ Co-authored U.S. regulatory strategy and led pre-submission meeting with FDA.
Drove double-digit revenue growth for Conmed’s largest division ($500M annual revenue). Shared responsibility for corporate revenue, income, and EPS goals. P&L responsibility for commercial team spanning four medical device portfolios in minimally invasive, robotic, and open surgery. Led remote team of 30 and $12M budget. ^ Accelerated double-digit revenue growth for Conmed with launch of AirSeal Robotic Solution – fastest new product in company history to achieve $10M revenue with 60K procedures (11 months). ^ Increased profit $13M and improved margins over two years with revamped pricing strategy. ^ Refined new product design process increasing speed to market and reducing R&D costs. Saved $600K and 6 months in pre-clinical trials for largest innovation in pipeline. ^ Dramatically improved team’s Gallup Engagement Score in first year from 29th to 74th percentile. ^ Developed Conmed’s first ever integrated digital marketing campaign, delivering 35% procedure growth. ^ Collaboration expanded the role of marketing from sales support to fully integrated commercial team. ^ Leveraged personal KOL network to increase sales, optimize product portfolio, and accelerate pipeline. ^ Implemented several company-wide process improvements to build foundation for sustainable growth
Selected by private equity owners (Savitr Capital) to turnaround pre-commercial biosurgery company developing fistula repair products. Responsible for P&L, finance, product development, manufacturing, R&D, regulatory, clinical trials, and Chief Commercial Officer. Quickly assessed clinical performance and IP to pivot strategy from medical device to drug delivery. Reported to Board of Directors, managed 30 FTE and $20M operating expense. ^ Reduced cash burn 30% to extend life of the company 6 months through pipeline prioritization, operations consolidation, team restructuring, and cost-cutting. ^ Reduced cost-of-goods 35% through product refinements and contract negotiation with leading CMO. ^ Revamped failing quality management system, documented procedures, and completed transition of CE mark to BSI Notified Body and latest ISO 13485:2016 with zero inspection observations. ^ Developed network of KOL’s to review R&D pipeline and stem cell drug delivery combination therapy. ^ Positioned company’s IP assets for sale when lead product had mixed clinical results.